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Abstract
Introduction: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are common inﬂammatory conditions. The diagnosis of
PMR/GCA poses many challenges since there are no speciﬁc diagnostic tests. Recent literature emphasizes the ability of 18F-
ﬂuorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to assess global disease activity in
inﬂammatory diseases. 18F-FDG PET/CT may lead to the diagnosis at an earlier stage than conventional imaging and may also
assess response to therapy. With respect to the management of PMR/GCA, there are 3 signiﬁcant areas of concern as follows:
vasculitis process/vascular stiffness, malignancy, and osteoporosis.
Methodsandanalysis:All patients with suspected PMR/GCR referred to the Rheumatology section of Medicine Department at
Svendborg Hospital, Denmark. The 4 separate studies in the current protocol focus on: the association of clinical picture of PMR/
GCA with PET ﬁndings; the validity of 18F-FDG PET/CT scan for diagnosis of PMR/GCA compared with temporal artery biopsy; the
prevalence of newly diagnosed malignancies in patients with PMR/GCA, or PMR-like syndrome, with the focus on diagnostic
accuracy of 18F-FDG PET/CT scan compared with conventional workup (ie, chest X-ray/abdominal ultrasound); and the impact of
disease process, and also steroid treatment on bone mineral density, body composition, and vasculitis/vascular stiffness in PMR/
GCA patients.
Ethicsanddissemination:The study has been approved by the Regional Ethics Committee of the Region of Southern Denmark
(identiﬁcation number: S-20160098) and Danish Data Protection Agency (J.nr 16/40522). Results of the study will be disseminated
via publications in peer-reviewed journals, and presentation at national and international conferences.
Abbreviations: 18F-FDG PET/CT = 18F-ﬂuorodeoxyglucose positron emission tomography/computed tomography, BMD =
bone mineral density, DXA = dual-energy X-ray absorptiometry, EULAR = European League Against Rheumatism, GCA = giant cell
arteritis, LV-GCA = large-vessel GCA, PMR = polymyalgia rheumatica, PWV = pulse wave velocity, TAB = temporal artery biopsy.
Keywords: ﬂuorodeoxyglucose, giant cell arteritis, osteoporosis and malignancy, polymyalgia rheumatica, positron emission
tomography/computed tomography, temporal artery biopsy, vascular stiffness, vasculitis
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1. Introduction
Polymyalgia rheumatica (PMR) is the most common inﬂammatory
rheumatic disease that affects individuals over the age of 50 years.
The typical symptoms of PMR are bilateral aching and stiffness in
selectedmuscle groups, predominantly in the neck, shoulders, upper
arms, andpelvic girdle that aremost pronounced in themorning and
improve with physical activity.[1–3] Giant cell arteritis (GCA) is an
inﬂammatory vasculopathy that typically involves medium and
large arteries.[4] Though involvement of the extracranial branches of
the carotid artery can be identiﬁed in the classic cranial GCA, GCA
may also involve aorta and its major branches, predominantly
branchesof theproximal aorta, that is, subclavian, axillaryproximal
brachial arteries, representing a subset of patients with large-vessel
GCA (LV-GCA).[4,5] Vasculitis, if untreated, can result in ischemic
complications, such as ischemic optic neuropathy, which is
responsible for vision loss in 10% to 15% of patients. Whereas
the etiology of PMR/GCA is still unknown, genetic and environ-
mental factors may play roles in the development of PMR/GCA.
GCA and PMR share many pathogenetic and epidemiological
features, and are frequently thought to represent different spectrums
of the same clinical entity. Despite the high association between
PMR and GCA, it is essential to differentiate these 2 conditions due
to different steroid treatment regimes. Corticosteroids are consid-
ered the treatment of choice for PMR/GCA, with higher doses
required for GCA.[1–3] PMR/GCA is generally not associated with
reduced longevity; however, patients with aortic aneurysm/dissec-
tion have higher rates of mortality.[6] Additionally, patients are at
risk of different comorbidities, both due to the disease characteristic
itself and also due to treatment side effects.
Accurate diagnosis of PMR/GCA can be challenging since
various diseases mimic these conditions and there are no speciﬁc
diagnostic tests. PMR is a clinical diagnosis. Careful clinical
evaluation and exclusion of several mimics of PMR/GCA can
support the diagnosis.[1–3] In cases of suspected GCA, temporal
artery biopsy (TAB) should be performed to conﬁrm the
diagnosis. However, it is invasive, it can be false-negative in a
proportion of patients, and it does not delineate the extracranial
component of the disease.[7,8] Laboratory ﬁndings are nonspeciﬁc
in PMR/GCA. Marked elevations in erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) are frequently seen in
PMR/GCA. Thrombocytosis, anemia, and increased alkaline
phosphatase may also be presented.[1,3] Different imaging
modalities, for example, ultrasonography (US), magnetic reso-
nance imaging, and angiography, are helpful in the diagnosis of
PMR/GCA; however, use of these modalities may be limited due
to long assessment time for wide vascular assessment, interob-
server variation, invasiveness, diminished sensitivity, speciﬁcity,
and so on.[9–11] There have been several proposed diagnostic
criteria for PMR.[12–15] The core components included in these
diagnostic criteria were as follows: an age cut-off point, bilateral
shoulder or hip pain, morning stiffness, elevated ESR, elevated
CRP, rapid steroid response, and disease duration. In 2012, the
provisional classiﬁcation criteria for PMR has been published by
European League Against Rheumatism (EULAR) and American
College of Rheumatology (ACR).[10] However, it is worth
mentioning that these are classiﬁcation criteria and are designed
to differentiate PMR from other diseases thatmimic PMRand are
not useful to make the diagnosis. Furthermore, the speciﬁcity of
the 2012 provisional classiﬁcation criteria for PMR seems to be
not sufﬁcient, despite high sensitivity.[16]
Positron emission tomography/computed tomography (PET/
CT) is a whole-body scan combining molecular and structural
imaging in a single examination. The principle is tomographic
detection of radiation from intravenously administered radio-
labeled tracers targeting disease processes on a cellular or
molecular level. Due to its high sensitivity and an inborn ability
for quantiﬁcation, PET can detect diseases at their very early stage
and grade their degree of activity.[17,18] The most versatile and
widely used tracer, 18F-ﬂuorodeoxyglucose (FDG), is a glucose
analog depicting local hypermetabolism (ie, inﬂammation or
cancer). In the clinic, it has mainly been used to detect focal
hypermetabolism due to cancer, and the impact in the oncologic
domain has been huge as PET/CT appears to cause a change in
management in as many as every third patient.[19] However, FDG
is nonspeciﬁc for cancer as inﬂammatory lesions also show
increased FDG uptake. This was until recently seen as a downside
resulting in “false-positive” ﬁndings in oncology, but is now
considered a great asset, since this allows for detection and
characterization of inﬂammatory processes in many settings.
18F-FDG PET/CT is being investigated clinically in amultitude of
inﬂammatory disorders. High sensitivity, high target-to-back-
ground contrast, accurate anatomical localization of sites of
inﬂammation, and an absolute quantiﬁcation potential may all
lead to early assessment of disease processes and their extent.[20]
With regard to vasculitis, recent literature emphasizes the
ability of 18F-FDG PET/CT to assess inﬂammation in the vessel
walls, whereas FDG uptake patterns in PMR are not yet ﬁrmly
established. It may locate disease at an earlier stage than
conventional imaging and assess response to therapy. Response
assessment is based on changes in glucose metabolism from
baseline to post-treatment follow-up, and the rates of change are
different in responders and nonresponders.[21] Besides locating
focal disease, 18F-FDG PET/CT may also assess disease activity
more globally, which may be especially interesting in systemic
inﬂammatory diseases. Thus, this research protocol will also
incorporate assessment of global disease assessment (ie, “global
disease burden”), a novel approach to quantifying disease. By
way of novel software-based quantitative methods, the radioac-
tivity throughout the body can be quantiﬁed, summed, and
presented as 1 single number, the systemic inﬂammatory activity
or “global disease burden.” The method is new and not yet ﬁrmly
established, but it holds signiﬁcant promise, especially for
response assessment in systemic inﬂammatory diseases.[22,23]
Therefore, we plan to conduct a prospective study to explore
the role of 18F-FDG PET/CT scan in the management of PMR/
GCA. In addition, 3 signiﬁcant areas of concern in the
management of PMR/GCA including: osteoporosis due to
steroid treatment or disease characteristics itself, malignancy,
and vasculitis/vascular stiffness will be investigated during the
project. This research protocol consists of four separate studies
designed to achieve below mentioned objectives that are
discussed individually later in the text (Fig. 1).
2. Objectives
2.1. Primary
The primary objective of this study is to explore the association of
18F-FDG PET/CT ﬁndings and uptake patterns (PET positivity/
negativity) and the clinical picture of PMR/GCA.
2.2. Secondary
1. To investigate the validity of 18F-FDG PET/CT scan for
diagnosis of PMR/GCAcomparedwith temporal artery biopsy.
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2. To compare the efﬁcacy of nationally recommended conven-
tional diagnostic workup to detect occult malignancies in the
setting of PMR/GCA (ie, chest X-ray [CXR] plus abdominal
US) with 18F-FDG PET/CT at diagnosis and during the ﬁrst
year after diagnosis.
3. To evaluate the inﬂuence of inﬂammation on regional and
total bone mineral density (BMD) and body composition,
and also vasculitis/arterial stiffness of aorta at diagnosis of
PMR and within a year after treatment initiation with
prednisolone.
2.3. Patient research partners (PRPs)
Active collaboration between patients and researchers is
relatively a new concept in the research ﬁeld which is a useful
tool to capture the patient perspective. By means of this, better
representation of patients’ needs and uncertainties can be
secured. It additionally avoids potential mismatch between
patients’ preferences and researchers objectives. EULAR has
introduced the recommendation for the inclusion of patient
representatives in scientiﬁc projects.[24] This research protocol
will also adhere to the EULAR recommendation. Thus, 2 PRPs
(co-authors Hanne Andersen and Rudolf Olsen) were invited to
help us design the study. The involvement of PRPs with respect to
8 signiﬁcant aspects of EULAR recommendation is depicted in
Table 1.
3. Methods and analysis
3.1. Study setting
The current study will be performed at the Department of
Rheumatology, Svendborg Hospital, Odense University Hospi-
tal, Svendborg, Denmark. The Rheumatology Department of
Svendborg Hospital has the capacity of enrolling PMR/GCA
patients that are required for this study, since all patients from all
over Funen County with suspicious PMR/GCAwill be referred to
the Diagnostic Center for primary investigation at Svendborg
Hospital. After conﬁrmed PMR/GCA condition the patients will
be referred to the local Rheumatology department for study
inclusion.
All parts of the project will take place at Svendborg Hospital,
except the 18F-FDG PET/CT scans and bone densitometry,
which will be undertaken at the Department of Nuclear Medicine
and Department of Endocrinology, respectively, Odense Univer-
sity Hospital, Odense, Denmark. The 18F-FDG PET/CT will be
performed as routine whole-body scan (from vertex of the skull to
the knees) 60 minutes after injection of a weight-adjusted dose of
FDG according to the guidelines from the European Association
of Nuclear Medicine.[25] The CT-part is a low-dose CT without
contrast enhancement.
3.2. Length of study (study I–IV)
The study was conducted till 1 year after the enrollment of last
patient.
3.3. Participants
All new patients with clinical suspicion of PMR/GCA will be
offered to be included in the study. At least 5 (A–E) components of
the PMR diagnostic criteria, including: age ≥50 years, bilateral
shoulder or hip pain, morning stiffness lasting >45minutes,
elevated ESR, elevated CRP, disease duration>2 weeks, should be
met to suspect PMR.[3] For GCA, the following criteria must be
considered: age >50 years, ESR/CRP >50, and also at least 2
symptoms related to vasculitis (scalp tenderness, vision disturban-
ces, headache [newor changed], jaw claudication, tenderness of the
temporal arteria) if patients donot simultaneously havePMR. If the
patient is suspected for PMR, 1 cranial symptom is enough to
suspectGCA. Besides, clinical suspicion of LV-GCA, that is, upper-
extremity claudication, upper-extremity blood pressure discrep-
ancies, and abnormal radial pulse, will be registered.
The exclusion criteria (study I–IV) are as follows:
1. Patients with dementia or inability to communicate in Danish
Figure 1. Summary of study I to IV. GCA=giant cell arteritis, PMR=
polymyalgia rheumatica, TAB= temporal artery biopsy.
Table 1
Patient research partners (PRPs).
1 Two patient research partners have participated in the study design and approved the current protocol.
2 The PRPs are considered to participate in all parts of the study. They have initially acknowledged the main idea of the study. Different aspects of the study including ethical
issues, relevance, feasibility, quality of the study have been discussed with the PRPs. It is expected that PRPs and investigators have meetings biannually to discuss the
process and primary results in details.
3 A number of 2 patients suffering from polymyalgia rheumatica are attached to the project.
4 The investigators provide the PRPs with a letter that clearly described the PRPs task and expected contributions.
5 The PRPs have fair communication skills and demonstrates constructive assertiveness. The PRPs are interested in the research ﬁeld.
6 The investigators will facilitate and encourage the contribution of PRPs, and consider their speciﬁc needs continuously, for example, educational and training aspects. In
addition, a safe and respectful environment will also be provided. The PRPs may contact the investigators in case of necessity.
7 The investigators provide information and training in the different aspects of the study to the extent that is appropriate, for example, ethical issues, study design and
prospective.
8 The PRPs contributions are voluntary and they have been offered co-authorship according to the Declaration of Helsinki.
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2. Infections or malignancy when prednisolone is permanently
unsuitable
3. Contraindication to imaging studies (pregnancy and blood
sugar [BS] >8mmol/L after 6hours fasting)
4. Initiation of steroid treatment before the 18F-FDG PET/CT
scan
5. Inability to provide informed consent
3.4. Study design
3.4.1. Study I: theassociationofclinicalpictureofpolymyalgia
rheumatica and giant cell arteritis with 18F-FDG PET/CT
ﬁndings: 1-year, prospective, blinded explorative study. The
current study is a 1-year prospective, blinded, and explorative
study. This is the ﬁrst study of its kind, to our knowledge, to
evaluate the association between the clinical picture of PMR/GCA
and 18F-FDG PET/CT ﬁndings in a prospective setting. Previous
study revealed the correlation between serological markers of
inﬂammation and FDG accumulation in PMR.[7,26–28] However,
the small sample size was a major limitation. On the contrary,
some reports failed to show this correlation.[9,29,30]
All included patients initially will undergo an 18F-FDG PET/
CT scan. The results of the 18F-FDG PET/CT scans will not be
made accessible to the treating physician in daily clinical routine,
but unexpected ﬁndings or ﬁndings requiring further diagnostic
tests or intervention will be relayed to the chief physicians
responsible for inclusion. The results of 18F-FDG PET/CT scan
will be blinded for both the clinicians and patients. During the
year after the initial 18F-FDG PET/CT scan, the following clinical
data will be monitored: cumulated prednisolone doses (using
patient diaries), well-being of the patients (including visual
analog scale [VAS], patient’s assessment of pain, morning
stiffness [minute], VAS for physicians’ evaluation), ESR, CRP,
ﬁbrinogen, and the eventual number of relapses. Deﬁnition of
remission and relapse is based on expert opinion considering the
following parameters: patient’s assessment of pain, morning
stiffness, ESR, CRP, clinical examination ﬁndings (eg, shoulder
pain/limitation, upper extremity blood pressure discrepancies,
vascular bruits and aortic regurgitation murmur), and steroid
dose which is required to control symptoms.
After 1 year, the 18F-FDG PET/CT results will be unveiled and
these parameters will be compared in the succeeding groups of
patients: patients with vasculitis in the large vessels (PET-positive);
patients without vasculitis in the large vessels (PET-negative);
patients with ﬁndings compatible with PMR (PET-positive);
and patients with vasculitis in the large vessels together with
ﬁndings compatiblewithPMR(PET-positive). The classiﬁcationof
18F-FDG PET/CT results (PET +/) is based on visual assessment
in a descriptive manner, and also quantitative methods. The visual
assessment is based on simple visual assessment of FDG uptake
patterns in a descriptivemanner (PMR) and a 4-point scale of FDG
uptake in the vessels (GCA). The visual assessment will be
compared with simple semiquantitative analyses, that is, so-called
maximum standard uptake value (SUVmax), a simple delineation
of the single voxels with the highest tracer uptake. This is a simple
procedure available with the generic software indigenous to the
scanners and providedby the vendors, for example, in our case,GE
Advantage Server 2.0 (GEHealthcare,Milwaukee,WI). It is easily
applicable in clinic, but highly variable and prone to both technical
and patient related pitfalls. Thus, a third method of quantiﬁcation
will be employed and compared with the visual assessment and
SUVmax, that is, global disease burden,[31] which is based onmore
elaborate, and therefore technically cumbersome, computations
involving segmentation, quantiﬁcation, and summing of all FDG-
avid lesions with pathologic activity deﬁned by predetermined
threshold. These metabolically active volumes (MAVs) will be
summed to yield a global disease score, a metabolic volume
product (MVP) of all PET-positive lesions throughout the body.
This seems to be a very robust method, but also somewhat
cumbersome to implement in daily clinical practice.
3.4.1.1. Image analysis. Images will be reviewed by 2 nuclear
medicine specialists at the Department of Nuclear Medicine at
Odense University Hospital who are blinded to clinical and
laboratory data. FDG uptake patterns will be recorded in a
descriptivemannerwith regard to nonarterial uptake and recorded
in 6 arterial compartments for each individual patient including
thoracic and abdominal aorta, carotid, subclavian, femoral, and
iliac arteries. A visual 4-point scale, as described by earlier
studies,[7,27–29] will be used for every arterial segment as follows:
1: Slight uptake but not negligible, lower than liver uptake
2: Intermediate uptake, similar to liver uptake
3: High-grade intense uptake, higher than liver uptake
A score of≥2 and<2will be considered PET-positive and PET-
negative, respectively. SUVs will be measured for quantitative
analysis for each arterial segment and calculated as follows:
SUV ¼ Q1 ðradioactivity in the region of interestÞ
Q2 ðradioactivity injectedÞ=WðweightÞ
Global disease burden will be expressed as follows:
cMVP=
P
(MAV∗cSUVmean), where
cMVP=partial volume corrected metabolic volume product,
MAV=metabolic active volumes, and
cSUVmean=partial volume corrected mean standard uptake
value
3.4.2. Study II: evaluating validity of 18F-FDG PET/CT scan
for diagnosis of polymyalgia rheumatica and giant cell
arteritis compared to temporal artery biopsy: an agreement
study.Recent literature is in favor of the ability of 18F-FDG PET/
CT scan to detect vasculitis at an early stage, which is important
to decide on treatment plan.[32] However, the superiority of 18F-
FDG PET/CT scan in comparison with TAB is still arguable. This
study will compare 18F-FDG PET/CT scan to TAB. As
mentioned in the study I, all included patients will undergo an
18F-FDG PET/CT scan. In addition to 18F-FDG PET/CT scan,
TAB will be performed before or within 1 week of steroid
treatment initiation. TAB will be taken by experienced
otolaryngologist at Department of Ear, Nose and Throat,
Svendborg Hospital. The results of biopsy will be compared
with the 18F-FDG PET/CT ﬁndings after 1 year, when the 18F-
FDG PET/CT results are revealed and compared with regards to
the degree of agreement between the 2 modalities.[33,34]
3.4.2.1. Temporal artery biopsy procedure. In patients with
lateralizing symptoms, the biopsy will be taken from the
symptomatic side. The superﬁcial temporal artery will be palpated
and marked with a surgical marker. The site will be shaved if is
necessary. Local anesthetic will be injected into the skin and
subcutaneous tissue corresponding to planned incision using
lidocaine 1% with or without adrenalin. Under sterile condition
the incision will be made at the previously marked skin site. The
incision should be large enough to uncover 2 to 3cm of the vessel.
The dissectionwill be carried through the subcutaneous fat and the
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artery will be identiﬁed just beneath the temporoparietal fascia.
The artery will be ligated proximally and distally, and so the
intervening segment will be cut out and ﬁxated in formaldehyde.
The in vivo specimen should beminimum1.5cm in length. At last,
skin will be sutured using non-absorbable suture material.
3.4.2.2. Preparation of specimens for pathologic examination.
The biopsy will be ﬁxed in formalin for 24hours, divided in
sections of 3 to 4mm, embedded in parafﬁn, cut in step sections,
and stained with Weigert elastin and hematoxylin and eosin
(H&E), respectively. Additional sections will be cut for later
analysis. Some of the additional sections will include deeper
sections in the block to further evaluate the extent of the lesion.
The additional analysis will include immunohistochemistry for
inﬂammatory cells, proliferation markers andmarkers of ﬁbrosis.
3.4.3. Study III: prevalence of newly diagnosedmalignancies
in patients with polymyalgia rheumatica and giant cell
arteritis, or polymyalgia rheumatica like syndrome with
a focus on 18F-FDG PET/CT compared with CXR/abdominal
US: a blinded, prospective, explorative study.The relationship
between PMR/GCA and malignancies remains controversial.
There are several reports regarding the association of PMR and
malignancies. In a database study from Sweden, where 35,918
patients after hospitalization for GCA and PMR were included,
there was a marginally increased incidence of cancer in patients
with GCA compared with the general population (standardized
incidence ratio 1.19, 95% conﬁdence interval [CI] 1.06–1.23).
However, when evaluating malignancy risk in the ﬁrst year after
diagnosis of PMR or GCA, the standardized incidence ratio was
2.26 (95% CI 2.10–2.42).[35] Another study utilized the UK
General Practice Research Database and evaluated cancer risk in
2877 patients with PMR, without pre-existing cancer or vascular
disease and treated with corticosteroids, who were matched with
up to5age, sex, andgeneral practice patientswithout PMR.Over a
median follow-up of 7.8 years, 23.2% of patients with PMR
developed cancer compared with 19.5% of controls. The risk of
malignancy was increased in patients with PMR during the ﬁrst 6
months after diagnosis (hazard ratio [HR] 1.69, 95% CI
1.18–2.42).[36]However, the risk ofmisclassiﬁcation/misdiagnosis
in database studies is notable, which also points out the need for
studies with prospective design. Danish Rheumatology Associa-
tion recommends the screening for malignant diseases in PMR/
GCA patients.[3] Various malignancies can cause PMR-like
symptoms; therefore detailed assessment to exclude occult
malignancies seems to be rational, especially in patients with
atypical manifestations.[37,38] Patients with malignant disease may
alsopresentwith remitting seronegative symmetrical synovitiswith
pitting edema, which is a closely related condition to PMR.[39,40]
This study is a blinded prospective investigation. At diagnosis
all patients undergo a CXR and abdominal US, as recommended
by the Danish Rheumatology Association. The 18F-FDG PET/
CT scan in every included patient (as described in study I) will be
assessed with regards to malignancies before results are blinded
to the clinicians for 1 year. This assessment will be blinded to
other clinical and imaging results and ﬁndings on 18F-FDG PET/
CT scan will be compared with CXR/abdominal US results to
establish the relative diagnostic accuracy of these 2 strategies for
malignant and infectious diseases in PMR/GCA patients. In case
of detecting or developing any kinds of malignant disease during
the study, the patients will be referred to the relevant department
for further work-up and treatment. This will not be a reason for
exclusion, but depends on individual assessment of the patient.
18F-FDG PET/CT scan may also be repeated for individual
patient if necessary.
3.4.4. Study IV: consequences of steroid treatment for BMD,
body composition, and also vasculitis/vascular stiffness in
polymyalgia rheumatica and giant cell arteritis patients: 1-
year prospective study. Patients who are diagnosed with PMR/
GCA are at high risk of osteoporosis due to both disease
inﬂammatory process and corticosteroid treatment. Nonspeciﬁc
bone protection (lifestyle intervention) should be initiated at the
time of steroid therapy, and speciﬁc antiosteoporotic therapy soon
thereafter in patients with low BMD. The gold standard for the
diagnosis of osteoporosis is regional dual energy X-ray absorpti-
ometry (DXA)of the hip and spine.Whole-bodyDXAcan estimate
3 body compartments consisting of fat mass (FM), lean body mass
(LBM), and bone mass. DXA is currently considered the gold
standard for body composition assessment. Changes in whole
body bone mineral content (BMC) is a biological meaningful
measure of overall calcium balance over a time period, whereas
changes in regional BMDare probablymore predictive for fracture
risk. Changes in body composition due to inﬂammatory process
have previously been reported in rheumatoid arthritis.[41–43]
Patients with PMR/GCA are also exposed to different changes in
body compositions mainly due to inﬂammatory process; however,
this has not been evaluated before.
The vasculitis process in patients with classic cranial GCA
preferentially involves the extracranial branches of the carotid
artery; however, large vessel involvement of the aorta and its
primary and secondary branches may be involved in patients with
LV-GCA.[4] The extent of large artery involvement of GCA is
uncertain, but clinically apparent large-vessel disease comprises
an estimated 9% to 14% of cases. [44,45] LV-GCA patients have
symptoms and signs of vascular insufﬁciency and are usually
diagnosed with delays due to atypical manifestations, and also
inadequacy of GCA criteria for classifying these patients.[4]
Arterial distensibility has been deﬁned as a measure of the
artery’s ability to expand and contract with cardiac pulsation and
relaxation. Vasculitis and other risk factors (eg, aging,
hypertension, and arteriosclerosis) may cause alteration in the
structural and functional properties of the arterial wall, which
results in diminished arterial distensibility. When evaluating
arterial stiffness, the aorta is a main vessel of interest, because of
substantial contribution of abdominal and thoracic aorta to the
arterial buffering function.[46,47] Pulse wave velocity (PWV)
measurement is a simple, noninvasive, and reproducible method
to evaluate aortic stiffness, and can be measured from different
arterial sites. Common carotid artery and the femoral artery are 2
common sites to obtain pressure waveforms transcutaneously.
The distance covered by the waves is corrected to the surface
distance between the 2 recording sites and base of aorta (eg,
jugulum), and the time delay (or transit time) is measured using
the feet of the 2 waveforms (at the end of diastole, when the steep
rise of the wave front begins). PWV is subsequently measured as
the ratio of the distance to the time delay (PWV [m/s]=distance
[m]/transit time [seconds]).[46] Previous study was in favor of that
PMR is associated with increased aortic stiffness which may
improve upon reduction of systemic inﬂammation induced by
treatment with glucocorticoids.[48]
This study is a 1-year prospective investigation which assesses
2 different areas of concern in PMR/GCA patients, namely BMD
plus body composition and vasculitis/vascular stiffness of large
vessels (aorta). The following procedures will be performed in all
included patients:
Emamifar et al. Medicine (2017) 96:26 www.md-journal.com
5
1. PWV measurement of aorta at baseline and then every 3
months to assess large vessels involvement (aorta). The results
of PWV assessment, which will be automatically calculated
from measurements of pulse transit time and distance between
the 2 sites, will be compared with vasculitis found in the 18F-
FDG PET/CT (study I). The results of PWV of aorta will also
be assessed regarding the actual cumulated prednisolone dose
to ﬁnd out the effects of steroid treatment on the arterial
stiffness.
2. Whole-body DXA scan at baseline and after 1 year from the
initiation of study to evaluate BMD and body compositions.
The degree of the difference in the T score and body
composition (including lean body mass, fat mass, bone
mineral content, and BMD) will be compared with the
cumulated prednisolone dose and the total global disease
burden of the 18F-FDG PET/CT scan at baseline (study I).
3.4.4.1. Body composition measurement. Body mass index
(BMI) of patients will be calculated from weight/height2.
Individuals with BMI values <18.5kg/m2 are considered
underweight, 18.5BMI<25 as normal, 25 to <30 as
overweight. BMI values ≥30 indicates obesity.[49] LBM, FM,
BMD, BMC, and fat-free mass (FFM=LBM+BMC). FM and
FFM will be expressed as absolute kg and FM as percentage of
total mass as well. The reference value for FM% is 12% to 20%
for men and 20% to 30% for women.[50] FFM and fat mass
indices (FFMI and FMI) will also be calculated. An aged and
sexed matched European reference from Switzerland will be used
for cut-off values for being under lean and obese.[51]
Bone mineral density values will be presented as Z scores (the
numberof standarddeviations fromthemean inhealthyageandsex-
matched people) and T scores (the number of standard deviations
fromthemean inhealthyyoungsex-matchedpeople).Tscore2.5
will be considered as osteoporosis and T score<1 as osteopenia.
3.4.4.2. PWV assessment.After measuring blood pressure (BP),
aortic (aorta to femoral) and upper limb (aorta to radial) PWV
will be measured using SphygmoCor device. Aortic PWV will be
calculated from measurements of bulbus aorta and femoral
artery, and upper limb PWV will be calculated from measure-
ments of bulbus aorta and radial artery waveform. Aortic
augmentation index (the difference between the second and ﬁrst
peaks of the central arterial waveform expressed as a percentage
of the pulse pressure) with a standardization to a heart rate of 75
beats per minute will also be assessed, which is a predictor of
adverse cardiovascular events.
3.5. Clinical evaluation and laboratory tests (study I–IV)
Blood pressure, pulse, weight, and also BMI of all patients will be
collected at the ﬁrst visit. The following laboratory tests will be
recorded: hemoglobin, white blood cells and thrombocytes,
erythrocyte sedimentation rate, C-reactive protein, sodium,
potassium, lipid proﬁle, thyroid-stimulating hormone (TSH),
hemoglobin A1c (HbA1C), blood sugar, creatinine, liver function
test (LFT), alkaline phosphatase, calcium, vitamin D, creatine
kinase, immunoglobulin A, immunoglobulin M, immunoglobulin
G, antinuclear antibody (ANA), antineutrophil cytoplasmic
antibody (ANCA), IgM rheumatoid factor (IgM RF), anticyclic
citrullinated peptide (anti-CCP), S-ﬁbrinogen, prostate-speciﬁc
antigen (PSA), M component (blood and urine), serum-free light
chains (sFLC),urineprotein, urineanalysis, and electrocardiogram.
3.6. Treatment plan
3.6.1. Steroid treatment. Steroid treatment is based on a
modiﬁcation of the Danish Rheumatology Association Guide-
lines. Dose reduction or dose increase is also according to this
guideline. Prednisolone will be initiated after performing 18F-
FDG PET/CT scan (Table 2).
Table 2
Steroid treatment and types of visits for the included patients (in case of persistent response, normal CRP and no clinical symptoms).
Time, wks Visits type
∗
TAB +/ PMR/
visual disturbance +, mg
TAB +/ PMR/ visual
disturbance , mg
PMR/ESR or
CRP>50/TAB +, mg
PMR/ESR or
CRP<50/TAB , mg
Baseline Phy. 60–75 40 30 20
1 Lab test/Tel 60 40 30 20
4 Phy. 50 35 25 17.5
6 Lab test/Tel 45 30 22.5 15
8 Lab test/Tel 40 27.5 20 12.5
10 Nur. 35 25 17.5 10
12 Lab test/Tel 30 22.5 15 8.75
14 Lab test/Tel 25 20 12.5 8.75
16 Phy. 22.5 17.5 10 7.5
18 Lab test/Tel 20 15 8.75 7.5
20 Lab test/Tel 17.5 12.5 8.75 6.25
22 Nur. 15 10 7.5 6.25
24 Lab test/Tel 12.5 8.75 7.5 5
26 Lab test/Tel 10 8.75 6.25 5
28 Phy. 8.75 7.5 5 3.75
32 Lab test/Tel 7.5 6.25 3.75 2.5
36 Lab test/Tel 6.25 5 2.5 1.25
40 Nur. 5 3.75 1.25 0
44 Lab test/Tel 3.75 2.5 0 0
48 Lab test/Tel 2.5 1.25 0 0
52 Lab test/Tel 1.25 0 0 0
56 Phy. 0 0 0 0
CRP=C-reactive protein, ESR= erythrocyte sedimentation rate, Nur.=nurse consultation, Phy.=physician consultation, PMR=polymyalgia rheumatica, TAB= temporal artery biopsy, Tel.= telephone consultation.
∗
If there is high clinical suspicion of GCA and TAB is negative, patients will be treated as TAB-positive GCA patients.
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3.6.2. Osteoporosis prevention. Calcium (1200mg/d) plus
vitamin D (800U/d) and 70mg alendronate weekly (if Tscore
<1) will be prescribed to reduce risk of fracture.
3.7. Follow-up (study I–IV)
Detailed follow-up plan is summarized in Table 3.
In addition to the mentioned investigations, patients will be
invited in a coming investigation to perform a magnetic
resonance of aortae, and also heart CT scan after completion
of the study, to evaluate the risk of aneurisms, especially in the
patients with PET positivity of the large vessels. Furthermore, a
PWV measurement will also be done at that time.
3.8. Outcomes
The primary outcome measure are as follows:
1. To evaluate the cumulated prednisolone doses, VAS, patients’
assessment of pain, morning stiffness, VAS for physician
evaluation, biochemistry results, that is, ESR, CRP, and
ﬁbrinogen, and the eventual number of relapses at baseline and
during the ﬁrst year after treatment initiation (weeks 12, 24,
36, and 48) in patients with PET-positive and PET-negative as
described above.
The secondary outcome measures are as follows:
1. To elucidate the degree of agreement between PET positivity
(vasculitis in the large vessels, and also ﬁndings compatible
with PMR) and TAB positivity.
2. To elucidate the degree of agreement between PET negativity
(no signs of vasculitis in the large vessels) and TAB negativity.
3. To reveal the prevalence of malignancies in the patients
detected by the aim of 18F-FDG PET/CT scan and
subsequently compare to the prevalence of malignancies
detected by the aim of CXR plus abdominal US.
4. To reveal the prevalence of malignancies in the patients
detected by the aim of CXR plus abdominal US and
subsequently compare to the prevalence of malignancies
detected by the aim of 18F-FDG PET/CT scan.
5. To evaluate BMI, T score, Z score, LBM, FM, BMD, BMC,
FFM, FFMI, and FMI at baseline and after 1 year of treatment
initiation.
6. To evaluate aortic PWV, upper limb PWV, and aortic
augmentation index of included patients at baseline and
during treatment (weeks 12, 24, 36, and 48).
3.9. Sample size
This study is, to the best of our knowledge, the ﬁrst of its kind;
hence, formal power calculations were impossible to conduct due
to missing information from previous literature or local clinical
daily routine. In this exploratory study, the number of patients to
be included was set to 80, which enables the assessment of the
primary objective, that is, the difference in the cumulated
prednisolone dose within the ﬁrst year after diagnosis between
groups including a respective 95% CI, with sufﬁcient precision.
Moreover, 80 patients are deemed appropriate to assess the
secondary objectives for hypothesis generating purposes.
3.10. Recruitment
All patients with the suspicion of PMR/GCR are referred to the
Diagnostic Center, Svendborg Hospital. After primary investiga-
tion and evaluation, the eligible patients will be referred to the
Rheumatology Department of Svendborg Hospital for formal
enrolment in the study. Patients will be informed orally and
written about the voluntary nature of the participation and
project objectives, content, risks, and beneﬁts. A deliberation
time of 24hours will be considered from submission of the oral
and written information to obtain informed consent. Consent
statement will be reviewed, signed, and dated by the patient and
handed over to the department. The patient receives a signed copy
of the consent form and be informed of that he/she can withdraw
from the study at any time without any reason nor consequences.
Table 3
Schedule of assessment during the study.
Visit 1 2 3 4 5
Weeks 0 12 24 36 48
Inclusion/exclusion criteria X
Informed consent X
Medical history including evaluation of cranial symptoms X X X X X
Blood pressure, pulse rate, body mass index and weight X X X X X
Physical examination X X X X X
Electrocardiogram X
Hemoglobin, white blood cells and thrombocytes, ESR, CRP, lipid proﬁle, hemoglobin A1c, blood sugar, Na,
K, creatinine, liver function test, Ca, Vit D, TSH, creatine kinase, IgA, IgM, IgG, ANA, ANCA, IgM RF,
anti-CCP, S-ﬁbrinogen, PSA, M component, serum-free light chains, urine protein
X
Hemoglobin, white blood cells, thrombocytes, ESR, CRP, lipid proﬁle, blood sugar, creatinine, calcium, liver
function test, alkaline phosphatase
X X X X
Chest X-ray and abdominal US X
18F-FDG PET/CT X
Temporal artery biopsy X
Pulse wave velocity measurement X X X X X
Whole-body DXA X X
Patients diaries X X X X X
18F-FDG PET/CT=18F-ﬂuorodeoxyglucose positron emission tomography/computed tomography, ANA= antinuclear antibody, ANCA=antineutrophil cytoplasmic antibody, anti-CCP=anticyclic citrullinated
peptide, CRP=C-reactive protein, DXA=dual-energy X-ray absorptiometry, ESR= erythrocyte sedimentation rate, IgM RF= IgM rheumatoid factor, PSA=prostate-speciﬁc antigen, TSH= thyroid-stimulating
hormone, US=ultrasound.
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A scanned copy of patient consent will be added to the patient
electronic hospital record, and one additional copy will be stored
in a locked room at the department.
3.11. Data collection
A PhD student will be responsible for collecting data elements
from patient medical records, including: demographic data, vital
signs (BP, PR), weight, BMI, results of laboratory tests, ECG, and
diagnostic tests (18F-FDG PET/CT scan, CXR, abdominal US,
TAB, PWV assessment, and whole-body DXA scan), and also
cumulative prednisolone dose. Data will be entered into the
University of Southern Denmark Research Electronic Data
Capture (REDcap) database twice to minimize data entry errors.
3.12. Statistical analysis
It is anticipated that 80 participants are likely to be included
during a period of 1 year. The results will be considered as
signiﬁcant if P value<0.05. Statistical analysis has been discussed
below with respect to each individual study.
In study I, data will be descriptive (mean± standard deviation).
Comparisons of the data, between the PET-positive and PET-
negative patients, will be made with the Mann–WhitneyU test or
Student t test, depending on whether or not the distribution is
normal. When comparing 2 binary variables, the chi-square test
will be performed. Correlation analysis will be performed with
Pearson correlation test.
Study II consists of descriptive statistics and proportions of
agreement.
Study III consists of descriptive statistics. Comparisons
between groups will be made with McNemar test. The sample
size of 80 patients is sufﬁcient to indicate a difference of 15% in
detection rate of malignancies with 18F-FDG PET-CT scan as
opposed to CXR plus abdominal UL (with a signiﬁcance level of
5% (1-sided), power of 80%, and assuming discordant
proportions of 15% and 0%).[52]
Study IV consists of descriptive statistics. Univariate compar-
isons between groups will bemadewith theMann–WhitneyU test
or Student t test, depending on whether or not the distribution is
normal. When comparing 2 binary variables, the chi-square test
will be performed. Analysis of repeated measurements over time
will be done by means of mixed linear models, using standard
errors that allow for intragroup correlation, relaxing the usual
requirement that the observations be independent. Comparison of
the abovementioned baseline data,matched by age and sex,will be
made, to the extent that these data are available.
3.13. Ethical consideration
Initial and control blood samples will be taken regarding the
routine management of PMR/GCA patients. There is no further
risk, for example, pain or infection for included patients
compared with other patients not participating in this study.
The outpatient visit may take longer time due to systematic
history taking and physical examination, PWV assessment, and
so on, which is a disadvantage for a busy patient.
An 18F-FDG PET/CT scan exposes a patient to about 8mSv
radiation. The average per capita background radiation is 4mSv
per year in Denmark. The average lifetime risk of cancer is
approximately 25% for a 25-year-old person in Denmark. The
radiation dose from one 18F-FDG PET/CT scan increases this
risk to approximately 25.01%. In persons above 50 years of age,
the increased risk is even less.
Due to increased rate of malignancy in PMR/GCA, patients
may beneﬁt from 18F-FDG PET/CT scan, which detects possible
concurrent malignancies.
Whole-body DXA scan will be performed at baseline and a
year after which is appropriate for patients receiving steroids.
Evaluating fat mass takes place during the same session and
extends the study by about 5minutes which is acceptable. The
radiation dose of whole-body DXA is negligible.
Vascular stiffness will be measured by SphygmoCor in
conjunction with routine outpatient controls. This method is
completely noninvasive and takes about 15 to 30minutes.
Although performing 18F-FDG PET/CT scan together with
TAB is a disadvantage of this study, patients are hopefully not
required to do TAB in future. TAB may still be required in small
number of patients.
3.14. Research ethics approval
The present study protocol is approved by the Regional Ethics
committee of the Region of Southern Denmark (identiﬁcation
number: S-20160098) and Danish Data Protection Agency (J.nr
16/40522). This study is also registered at clinicaltrials.gov
(ClinicalTrials.gov Identiﬁer: NCT02985424).
3.15. Protocol amendment
Anymodiﬁcations to theprotocolwhichhave substantial effects on
the conduct of the study, potential beneﬁts to the patient or impact
on patient safety, including changes to eligibility criteria, patient
population, sample size, study objectives, study design, study
procedures, and treatment plan will require a formal amendment
to the protocol. Such amendment will be sent to the Ethics
committee for further approval before implementation. Adminis-
trative changes of the protocol deﬁned asminor corrections having
no effect on the way the study is to be conducted will be
documentedand theEthics committeemayalsobenotiﬁedof them.
3.16. Consent
The PhD student is responsible for obtaining informed consent
from potential participants or authorized surrogates. All
participants will be informed about the voluntary nature of
the participation in the study and will be received detailed
information about diagnostic and treatment modalities.
3.17. Conﬁdentiality
The PhD student will give a unique code to each participant
which will be used to identify them during the study. Any kinds of
paper reports, laboratory specimens, administrative form, and so
on will be identiﬁed by theses codes. All data collection sheets,
patients consent forms, daily registration chart, and so on will be
secured in an ofﬁce with limited access. All digital ﬁles will be
saved in our local databases which are password protected.
3.18. Dissemination
The current study is a large-scale study and will form the basis of
a PhD thesis. The hard copy of our work will be available at the
University of Southern Denmark library once completed. The
results of the study are intended for the following potential papers
(preliminary titles) that will be sought published in international
peer reviewed journals, or presented at International or national
congresses orally.
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1. The clinical picture in PMR/GCA patients with and without
PET detected vasculitis.
2. Validity of 18FDG PET-CT scan for diagnosis of PMR/GCA
compared with TAB: An agreement study.
3. Prevalence of newly diagnosed malignancies in PMR/GCA
patients with the aim of 18F-FDG PET/CT scan and CXR/
Abdominal US: A blinded prospective study.
4. Effects of steroid treatment on Bone mineral density and body
composition in PMR/GCA patients: A prospective study.
5. Effects of steroid treatment on vasculitis/vascular stiffness of
PMR/GCA patients with the aim of PWV measurement: A
prospective study.
After the completion of data collection, no later than 3 years,
we will deliver a deidentiﬁed dataset to a suitable data archive for
sharing purposes.
4. Discussion
The proposed study will explore the potential role of 18F-FDG
PET/CT scan in the early diagnosis andmanagement of PMR/GCA
before initiation of steroid treatment, and also the association
between 18F-FDG PET/CT ﬁndings and the clinical picture of the
patients. Though18F-FDGPET/CT is not yet capable of evaluating
temporal artery due to inadequate resolution, the extracranial
involvement of large vessels, mainly thoracic aorta, carotid, and
subclavian, can be delineated.[53] Patients with positive 18F-FDG
PET/CT ﬁndings will be classiﬁed as having GCA and not isolated
PMR, which is of great importance in the clinic due to different
steroid treatment regimes. Besides, GCA patients with aortic
involvement are at increased risk of aneurysm formation, who seek
close monitoring.[54] It is our hope that our results elucidate the 3
main areas of concern regarding the management of PMR/GCA
including: malignancy, osteoporosis/changes in body composition,
the vasculitis process, and the interaction between them, and
ultimately elucidate factors predictive of the disease outcome.
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